Detail akcie Immunovant Rg online

Business Summary: Immunovant, Inc. is a clinical-stage immunology company enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-fragment crystallizable receptor (FcRn) technology, the Company is developing targeted therapies to meet the complex and variable needs of people with autoimmune diseases. Its product pipeline includes its product candidates, IMVT-1402 and batoclimab, both of which are novel, fully human, monoclonal antibodies that target the neonatal FcRn. Subcutaneous injections, IMVT-1402 and batoclimab have been observed to reduce immunoglobulin G (IgG) antibody levels, which has provided evidence supporting the use of an anti-FcRn antibody in disease areas associated with high levels of pathogenic IgG antibodies. The Company is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD).
Financial Summary: BRIEF: For the nine months ended 31 December 2025, Immunovant Inc revenues was not reported. Net loss increased 16% to $357.8M. Higher net loss reflects Clinical-stage biopharmaceutical segment loss increase of 15% to $373.3M. Basic Earnings per Share excluding Extraordinary Items increased from -$2.10 to -$2.04.